MONTREAL, Jan. 18 /CNW Telbec/ - A large international research group led by Dr. Tarik Möröy, a researcher at the Institut de recherches cliniques de Montréal (IRCM), has discovered that a variant of the gene "Growth Factor Independence 1" (GFI1) predisposes humans to develop acute myeloid leukemia (AML), a certain subtype of blood cancer. This study was coordinated by Dr. Möröy at the IRCM in collaboration with multiple international study groups located throughout Germany, the Netherlands and the United States. This new finding has been prepublished online in Blood, the Journal of the American Society of Hematology. Dr. Cyrus Khandanpour, medical doctor and postdoctoral fellow in Dr. Möröy's group at the IRCM, is the first author of the study.
The study describes and validates the association between a variant form of GFI1 (called GFI136N) and AML in two large patient cohorts (comprising about 1,600 patients from Germany and the Netherlands) and the respective controls. The association between GFI136N and other already established markers in the field of AML was examined in collaboration with several study clinics in Rotterdam, Nijmegen (Netherlands), Dresden, Essen, Munich (Germany), Columbus and City of Hope (USA) showing that GFI136N is a new independent marker for predisposition to AML. "This extensive collaboration effort resulted in one of the largest association studies published in the field of AML," pointed out Dr. Möröy.
The researchers performed different examinations showing that GFI136N behaves differently than its more common form. "A possible explanation for the predisposition to AML this variant leads to," mentioned Dr. Khandanpour, "is that it cannot interact with all the proteins the more common GFI1 usually interacts with. One reason for this is a different localization of this variant within the cell, but different functions of the variant at the molecular level may also account for this behaviour."
Carriers of this variant have a 60% higher risk of developing AML. This study brings new insight on the development of AML and suggests also that GFI136N might be used in the future as a new biomarker for evaluating prognosis in AML patients.
This work was supported in part by a grant from CRS-The Cancer Research Society (Canada) to Dr. Möröy and by the COLE Foundation, which granted a fellowship to Dr. Khandanpour.
References for this article are available at:
Blood First Edition Paper, prepublished online January 15, 2010; DOI 10.1182/blood-2009-08-239822
Dr. Tarik Möröy is President and Scientific Director of the IRCM, Full Research Professor IRCM and Director of the Research Unit on Hematopoiesis and Cancer at the IRCM. He is also Full Research Professor in the Department of Microbiology and Immunology and accredited member in the Department of Biochemistry at the Université de Montréal. In addition, he is Adjunct Professor in the Department of Biochemistry and a member of the Division of Experimental Medicine at McGill University. Dr. Möröy holds a Tier 1 Canada Research Chair in Hematopoiesis and Immune Cell Differentiation. Dr. Cyrus Khandanpour is a medical doctor and postdoctoral fellow in Dr. Möröy's laboratory and holder of a COLE Foundation fellowship.
Established in 1967, the IRCM (www.ircm.qc.ca) now has 36 research units specialized in areas as diverse as immunity and viral infections, cardiovascular and metabolic diseases, cancer, neurobiology and development, systems biology and medicinal chemistry, clinical research and bioethics. It has a staff of more than 450 people. The IRCM is an independent institution, affiliated with the Université de Montréal and its clinic is associated to the Centre hospitalier de l'Université de Montréal (CHUM). The IRCM holds a close collaboration with McGill University.
SOURCE Institut de recherches cliniques de Montréal (IRCM)
For further information: For further information: Tarik Möröy, PhD, Director of the Research Unit on Hematopoiesis and Cancer and President and Scientific Director of the IRCM, http://www.ircm.qc.ca/en/recherche/statique/unite45.html; Olivier Lagueux, Communications Officer, (514) 987-5555, email@example.com; www.ircm.qc.ca